Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Torasemide extended release - Sarfez Pharmaceuticals

Next Previous
Search
Drug Profile

Torasemide extended release - Sarfez Pharmaceuticals

Alternative Names: SOAANZ; Torsemide extended release - Sarfez Pharmaceuticals

Latest Information Update: 13 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sarfez Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfonamides
  • Mechanism of Action Loop diuretics; Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Oedema

Most Recent Events

  • 26 Mar 2025 Sarfez Pharmaceuticals terminates a phase II trial for Oedema (renal sodium excretion in heart failure) in USA (PO) (NCT06176794)
  • 31 Mar 2024 Sarfez Pharmaceuticals initiates a phase II trial for Oedema (overactive bladder in heart failure) in USA (PO) (NCT06206512)
  • 11 Mar 2024 Sarfez Pharmaceuticals initiates a phase II trial for Oedema (renal sodium excretion in heart failure) in USA (PO) (NCT06176794)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top